George Leong edits the Pennies to Millions newsletter for Lombardi, and he’s got an ad out now touting three different “penny stocks” that could make you buckets of cash … … the basic pitch is for “unknown” or “hidden” stocks with “home run” potential, and generally at fairly low prices (using “penny stocks” in the […]
I like Frank Curzio’s podcast (now called Wall Street Unplugged), and I generally find his way of thinking interesting, so after he was laid off by Porter Stansberry I was half hoping he’d go off on his own and build his own newsletter business from scratch (he edited Phase 1 Investor and Small Cap Specialist […]
Well, again Frank Curzio’s Phase 1 Investor wins the prize for “teaser ad most Gumshoe readers are asking about” … so let’s give it a gander for you. Phase 1 is a premium-priced ($3,500 is the current “on sale” cost) small cap newsletter published by Stansberry, and it tends to be among the most-requested letters […]
Today we have to put my usual cautionary note up top. The stock Frank Curzio is pitching as the key supplier for “The 20-Second Battery” is ridiculously small. It has already been recommended to his subscribers over at Phase 1 Investor, so presumably they’ve gotten their fill of the stock (he also touted it about […]
There’s been a quick burst of interest from Gumshoe readers about Frank Curzio’s latest teaser pitch … and like a fuzzy little puppy, I aim only to please, so we’ll get an answer for you as quickly as we can. OK, not all that quick — we do have our customary blatheration and hemming and […]
Buy this ‘Under $0.50’ Stock by November 1st, 2013 “This is one of the few times in the history of our business we have recommended a company so small and with such high upside potential. A triple-digit gain within the next 12-36 months is highly possible…. “We’ve been vetting the opportunity for nearly two years.” […]
Well, you probably know the drill by now — if there’s going to be a teaser pitch made for a $5,000 (or $3,000 “on sale”) newsletter, and if that pitch is going to be made by probably the largest marketer in the newsletter world, well, yours truly is going to be inundated with requests to […]
Well, well, well — another month, another Phase 1 teaser from Frank Curzio and the Stansberry folks. And if you’re going to use your massive mailing list of a few million investors to sell a $3,000 newsletter that most of them won’t ever consider, well, you can pretty much predict that the queries will make […]
Phase 1 Investor is the big kahuna newsletter at Stansberry & Associates, the $5,000 newsletter that they typically discount to $3,000 when sending out promo emails … … and they market this letter so heavily that Gumshoe readers flood our inbox whenever a new Phase 1 teaser ad runs. So … another of their teasers […]
The folks at Phase 1 Investor, the “big ticket” newsletter from Stansberry & Associates currently helmed by Frank Curzio, tend to love teensy weensy biotech and mining stocks — so when the teaser from Curzio hit my inbox this week for a more traditional tech stock with a more reasonable market cap, I sat up […]
“The last time this happened, early investors had an opportunity to make a fortune. Now one team of researchers thinks it’s happening again… with an unusual, little-known mining stock.” That’s the opening of the latest teaser from Frank Curzio for his Phase 1 Investor newsletter, and it’s not the first time we’ve heard the promise […]
This teaser is going to get a lot of attention from Gumshoe readers, partly because Stansberry Phase 1 Investor teasers always get a lot of attention (they usually tease a small stock and they charge $5,000 for the newsletter, which gives them an aura of awesomeness — deserved or not), and partly because the pitch […]
This teaser has gotten a lot of attention from my readers, as do all the pitches thrown by the folks at Stansberry’s Phase 1 Investor newsletter — you just know that if you charge $5,000 for a subscription, and use one of the world’s largest investor mailing lists to tease a tiny stock in order […]
Just to keep you up to date on my personal portfolio, I need to tell you that today I picked up a few shares of Gold Standard Ventures, the pick that I uncovered for you from Phase 1 last week. This is very much a flier, based just on the speculation that the Stansberry teasers […]
I generally don’t like to write about super-heavily-hyped microcap stocks for the whole Gumshoe readership, because we’re almost guaranteed to cause a spike in the price for that stock. So when I saw the latest teaser for the Phase 1 folks over at Stansberry, and those teasers always cause a huge flood of emails to […]
We have a charming little tradition here at Stock Gumshoe of picking out the stinkiest stock to have been teased over the past year, and calling it our “Turkey of the Year” come Thanksgiving time. It’s not particularly fair — certainly not to turkeys everywhere, and probably not to the newsletter folks who use breathless, […]
I suppose I should expect this by now — whenever Frank Curzio and the gang put out a teaser for Phase 1 Investor, which is the big-money newsletter from Stansberry & Associates ($5,000/year, though almost always “on sale” at $3,000 when they’re running promos), my inbox gushes like Spindletop. Didn’t matter if it was a […]
Here’s the lead-in to the latest ad for the Global Resource Alert “I’m Peter Krauth and I’d like to tell you a story about a “private vault”… “A ‘vault’ that contains nearly one million ounces of 99.9% pure gold bars ready for market, ready to sell for nearly $1.4 billion at today’s spot price. “This […]
I always love to see a new teaser from Phase 1 Investor, the high-price newsletter offered as the “ultimate upgrade” by the Stansberry & Associates folks — the stocks usually are interesting, they’re often tiny and move like crazy after the teaser campaign, and the marketing language is always plenty florid to justify the $5,000 […]
You can always count on a good story from a Phase 1 teaser — Phase 1 is the fancy top-of-the-line upgrade newsletter from Stansberry & Associates ($5,000/year, though it’s usually “on sale” for $3,000 when they’re promoting it as they are now), currently edited by Frank Curzio, and it has historically focused on lots of […]
I certainly don’t mean to impugn those without sight or hearing, but if you can read or listen, and have ever given your email address to any kind of financial website, chances are pretty good that you’ve been pitched this week about the “Chi-Tab” by Frank Curzio for his pricey Phase 1 newsletter at Stansberry […]
Those who’ve been with the Gumshoe for a while know that it’s tough to top Stansberry’s Phase 1 Investor for marketing that uses over-the-top hyperbole about tiny biotech and mining stocks, and creative names that obscure the truth behind their investments — that doesn’t seem to have changed much with the new(ish) guy at the […]
Well, as I noted in the Daily Update email on Friday, the Thermogenic Oil teaser from the Stansberry folks has garnered more interest from my readers than anything else in recent months — so at the very least, that copywriter deserves a raise. And I also said I’d try to take a closer look and […]
Well, this seems like a good way to get back to work after a week of moving — and I must say, I’m relieved that it’s not a hugely difficult teaser, since the mighty Thinkolator is not yet up to speed after the move. Hopefully I’ll find the rest of the pieces by next week. […]
Well, it didn’t take long for Porter Stansberry to get his newest analyst, Frank Curzio, to headline the Phase 1 Investor newsletter, their most expensive product — this is a letter that has focused mostly on biotech, other tiny tech stocks, and junior miners over the last couple years that I’ve written about them (at […]
I was going to hold off on writing about this teaser until Friday and cover it just for the Irregulars in the Friday File because it’s a tiny stock and I’ll very likely be influencing the price by writing about it for this larger group today — but I’ve gotten so many questions in just […]
There’s a small stack of potential teasers just sitting and waiting for the attention of the Thinkolator, but your friendly neighborhood Gumshoe is but a humble servant to the masses of the assembled Gumshoe faithful … so when I start getting hundreds of questions about one specific teaser, that moves to the top of the […]
A large number of readers have sent in copies of the latest tease for Matt Badiali’s gold stock picks — Matt is the editor of the S&A Resource Report, a pretty popular but inexpensive (and therefore large) oil and commodities newsletter, but this time he’s sharing his picks only with the subscribers of Phase 1 […]
Late last week I wrote about a new teaser from the Phase 1 newsletter at Stansberry & Associates — as far as these things go it’s actually a relatively low-hype, fact-based teaser ad, since there’s a pretty big fundamental argument in favor of anyone who can profit from Iraq’s oil reserves (as well as lots […]
This ad is getting a lot of attention from my readers, if my inbox is any indication — it’s for the Phase 1 Investor service from Stansberry & Associates, which is their expensive premium letter that has historically focused mostly on biotech stocks but is also used by them for any super-tiny stocks that would […]
I don’t see this very often, but it looks like there’s a little battle brewing between Ian Cooper and Rob Fannon … or probably more precisely, between Stansberry & Associates and Angel Publishing. I don’t know if this has anything to do with it, but the two seem linked in several “sincerest form of flattery” […]
Stansberry & Associates’ Phase 1 Investor newsletter is teasing us about shares of a drug company: “On March 30, FDA results we’ve waited 2 years to receive could make you $195,600, overnight” — and they quote Porter Stansberry as saying that “This is the kind of situation that can change your life… where a $10,000 stake can allow you to literally quit work, forever.” Sounds nice, eh?
I haven’t written much about Rob Fannon and his Phase 1 Investor newsletter lately — this is the high end newsletter published by the folks at Stansberry and Associates, it’ll run you about $4,500 a year, and it’s largely focused on biotech companies. So is their advice worth more than the advice from less expensive […]
This teaser comes in from the folks at Stansberry’s Phase 1 Investor service, which is their uber-expensive $5,000 subscription newsletter that purports to find the best opportunities in the smallest stocks. They have developed what they call the L-2 Indicator that tells them when to buy stocks, in this case gold stocks: “the ‘L-2 Indicator’ […]
This teaser and the solution come in from our old friend Streetsifter, who has written up a few solutions in this space in the past — t0 the great appreciation of your Gumshoe. His solution has been confirmed by a few other readers who I know do a good job sniffing out solutions, so he’s […]
So that’s an attention-getting claim, eh? Wait, it gets better. This one comes to us from Porter Stansberry at Phase 1 Investor, who would like us to pony up … get ready for it … $5,000 for entry into the exclusive group of investors who are going to find out — in a report released […]
This one comes to us from Peter Stansberry as part of an ad for his Phase 1 Investor service … which he’d like you to subscribe to in exchange for learning about this fabulous company in a special report. In fact, he’s promising that his biotech analyst will reveal the name of this company on […]
Comments
No comments.